当前位置: 首页 > 期刊 > 《医药产业资讯》 > 202018
编号:13834371
外泌体与消化道肿瘤化疗耐药的研究进展(5)
http://www.100md.com 2020年6月25日 《中国医药导报》 202018
     [26] Kamerkar S,Lebleu VS,Sugimoto H,et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer [J]. Nature,2017,546(7659):498-503.

    [27] Ha D,Yang N,Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes:current perspectives and future challenges [J]. Acta Pharm Sin B,2016,6(4):287-296.

    [28] Aung T,Chapuy B,Vogel D,et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3 [J]. Proc Natl Acad Sci U S A,2011,108(37):15336-15341.

    [29] Zhang J,Zhang HD,Yao YF,et al. β-Elemene Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission via Exosomes [J]. Cell Physiol Biochem,2015,36(6):2274-2286.

    [30] Wang X,Zhang H,Bai M,et al. Exosomes serve as nanoparticles to deliver anti-miR-214 to reverse chemoresistance to cisplatin in gastric cancer [J]. Mol Ther,2018,26(3):774-783.

    [31] Liang G,Zhu Y,Ali DJ,et al. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer [J]. J Nanobiotechnology,2020,18(1):10.

    (收稿日期:2020-02-14 本文編辑:刘明玉), http://www.100md.com(倪修凡 张尤历 徐岷)
上一页1 2 3 4 5